Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

191.70SEK
7:24am EST
Change (% chg)

0.30kr (+0.16%)
Prev Close
191.40kr
Open
191.40kr
Day's High
195.00kr
Day's Low
191.35kr
Volume
287,714
Avg. Vol
985,151
52-wk High
299.60kr
52-wk Low
110.00kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.57
Market Cap(Mil.): kr34,172.46
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 46.65 31.13 34.39
EPS (TTM): 2.69 -- --
ROI: 8.68 15.55 14.96
ROE: 12.91 16.92 16.52

BRIEF-FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis

* FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)

Nov 20 2018

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

Jul 20 2018

Earnings vs. Estimates